[go: up one dir, main page]

NO20065860L - Stabiliserte flytende interferonformuleringer - Google Patents

Stabiliserte flytende interferonformuleringer

Info

Publication number
NO20065860L
NO20065860L NO20065860A NO20065860A NO20065860L NO 20065860 L NO20065860 L NO 20065860L NO 20065860 A NO20065860 A NO 20065860A NO 20065860 A NO20065860 A NO 20065860A NO 20065860 L NO20065860 L NO 20065860L
Authority
NO
Norway
Prior art keywords
stabilized liquid
interferon formulations
liquid interferon
interferon
formulations
Prior art date
Application number
NO20065860A
Other languages
English (en)
Inventor
Fabrizio Samaritani
Alessandra Del Rio
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of NO20065860L publication Critical patent/NO20065860L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

En stabilisert HSA-fri flytende farmasøytisk sammensetning er beskrevet som omfatter et interferon (IFN), hvori nevnte formulering er en oppløsning som omfatter en buffer, en aminosyre og en antioksidant. Fortrinnsvis er interferonet humant rekombinant IFN-beta.
NO20065860A 2004-06-01 2006-12-19 Stabiliserte flytende interferonformuleringer NO20065860L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04076626 2004-06-01
US61637804P 2004-10-06 2004-10-06
PCT/EP2005/052414 WO2005117949A1 (en) 2004-06-01 2005-05-27 Stabilized interferon liquid formulations

Publications (1)

Publication Number Publication Date
NO20065860L true NO20065860L (no) 2006-12-19

Family

ID=34928261

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065860A NO20065860L (no) 2004-06-01 2006-12-19 Stabiliserte flytende interferonformuleringer

Country Status (14)

Country Link
US (1) US7731948B2 (no)
EP (1) EP1750751B1 (no)
JP (1) JP4988562B2 (no)
CN (1) CN1993139B (no)
AU (1) AU2005249233B2 (no)
BR (1) BRPI0510526A (no)
CA (1) CA2567310A1 (no)
EA (1) EA010979B1 (no)
ES (1) ES2418833T3 (no)
IL (1) IL179620A (no)
MX (1) MXPA06014078A (no)
NO (1) NO20065860L (no)
UA (1) UA92146C2 (no)
WO (1) WO2005117949A1 (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0416980A (pt) 2003-12-11 2007-02-21 Ares Trading Sa formulações lìquidas de interferon estabilizadas
JP2007538048A (ja) * 2004-05-17 2007-12-27 アレス トレーディング ソシエテ アノニム ヒドロゲル・インターフェロン製剤
CA2571800A1 (en) * 2005-12-23 2007-06-23 Canadian Blood Services Nitrophenyls and related compounds and thimerosal for the inhibition of immune related cell or tissue destruction
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
WO2008066322A1 (en) * 2006-11-28 2008-06-05 Daewoong Co., Ltd. A stable hsa-free and antioxidant-free pharmaceutical composition comprising interferon-beta
JP5513380B2 (ja) 2007-06-25 2014-06-04 アムジエン・インコーポレーテツド 肝細胞増殖因子に対する特異的結合剤の組成物
PT2234645E (pt) 2007-12-20 2012-05-21 Merck Serono Sa Formulações de peg-interferão-beta
CN105521491B (zh) * 2010-03-01 2020-03-24 西托戴恩有限公司 浓缩蛋白制剂及其用途
US20120269770A1 (en) * 2010-11-22 2012-10-25 Mark Brader Stable Preserved Compositions of Interferon-Beta
ES2666850T3 (es) * 2011-03-15 2018-05-08 Biogen Ma Inc. Procedimiento para reducir los síntomas similares a gripe asociados a la administración intramuscular de interferón usando un régimen de dosificación creciente de titulación rápida
RU2527701C1 (ru) * 2013-05-24 2014-09-10 Федеральное государственное бюджетное учреждение "Научный центр реконструктивной и восстановительной хирургии" Сибирского отделения Российской академии медицинских наук (ФГБУ "НЦРВХ" СО РАМН) Способ приготовления средства, обладающего свойством стимуляции регенерации хрящевой, костной, мышечной тканей и способ стимуляции регенерации хрящевой, костной, мышечной тканей с использованием приготовленного средства
AU2015239104B2 (en) * 2014-04-04 2018-12-20 Ares Trading S.A. Novel IFN beta protein analogs
US9375478B1 (en) 2015-01-30 2016-06-28 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
CN114053397B (zh) * 2022-01-17 2022-12-20 北京三元基因药业股份有限公司 一种稳定的干扰素多剂量注射液及其制备方法
CN120549858A (zh) * 2025-07-31 2025-08-29 长春生物制品研究所有限责任公司 重组人干扰素α1b溶液及其制备方法与应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4737462A (en) * 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4588585A (en) * 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4469228A (en) * 1983-05-31 1984-09-04 Schering Corporation Interferon kit
US4636383A (en) 1984-08-29 1987-01-13 Schering Corporation Interferon-cyclaradine combination
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US5017691A (en) 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US4879111A (en) * 1986-04-17 1989-11-07 Cetus Corporation Treatment of infections with lymphokines
US4965195A (en) * 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
IT1244511B (it) 1991-04-15 1994-07-15 Isi Ist Sierovaccinogeno Ital Idrogeli a base di policarbossilati sintetici e proteine per il rilascio controllato di farmaci e procedimento per la loro preparazione.
KR960009385B1 (en) * 1993-11-24 1996-07-18 Samsung Bp Chemicals Co Ltd Apparatus and method for wastewater treatment by activated sludge process type
IT1272252B (it) 1994-05-16 1997-06-16 Applied Research Systems Formulazioni liquide di interferone beta
JP2758154B2 (ja) 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
ZA9610374B (en) 1995-12-11 1997-06-23 Elan Med Tech Cartridge-based drug delivery device
DK0959873T3 (da) * 1996-12-20 2006-07-03 Alza Corp Gelsammensætning og fremgangsmåder
US6013253A (en) 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
US6923956B1 (en) * 1997-09-23 2005-08-02 Rentschler Biotechnologie Gmbh Liquid interferon-β formulations
JP2001526033A (ja) * 1997-12-08 2001-12-18 ジェネンテク・インコーポレイテッド ヒトインターフェロン−イプシロンというｉ型インターフェロン
CZ298579B6 (cs) 1998-04-28 2007-11-14 Applied Research Systems Ars Holding N. V. Konjugát polyolu a interferonu-beta
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
CA2379388C (en) 1999-07-13 2012-05-29 George N. Cox, Iii Immunoglobulin fusion proteins
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
PL354987A1 (en) * 1999-10-04 2004-03-22 Chiron Corporation Stabilized liquid polypeptide-containing pharmaceutical compositions
CN1175901C (zh) 1999-12-06 2004-11-17 天津华立达生物工程有限公司 一种稳定的干扰素水溶液
US6465425B1 (en) * 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
US6723606B2 (en) 2000-06-29 2004-04-20 California Institute Of Technology Aerosol process for fabricating discontinuous floating gate microelectronic devices
KR100396983B1 (ko) 2000-07-29 2003-09-02 이강춘 고반응성의 가지 달린 고분자 유도체 및 고분자와 단백질또는 펩타이드의 접합체
DE60130580T2 (de) 2000-12-27 2008-06-12 Ares Trading S.A. Lipidmikropartikel mittels kryogenischer mikronisierung
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
NZ535008A (en) 2002-02-08 2005-09-30 Alkermes Inc Polymer-based compositions for sustained release
US20040037809A1 (en) 2002-06-28 2004-02-26 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon beta
TWI272948B (en) * 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
AR044302A1 (es) * 2003-05-13 2005-09-07 Ares Trading Sa Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
JP2007538048A (ja) * 2004-05-17 2007-12-27 アレス トレーディング ソシエテ アノニム ヒドロゲル・インターフェロン製剤

Also Published As

Publication number Publication date
EP1750751B1 (en) 2013-04-10
CA2567310A1 (en) 2005-12-15
AU2005249233A1 (en) 2005-12-15
JP2008500996A (ja) 2008-01-17
US7731948B2 (en) 2010-06-08
CN1993139A (zh) 2007-07-04
US20070292391A1 (en) 2007-12-20
WO2005117949A1 (en) 2005-12-15
HK1102563A1 (en) 2007-11-30
JP4988562B2 (ja) 2012-08-01
IL179620A0 (en) 2007-05-15
MXPA06014078A (es) 2007-02-15
UA92146C2 (ru) 2010-10-11
EA010979B1 (ru) 2008-12-30
EP1750751A1 (en) 2007-02-14
AU2005249233B2 (en) 2010-10-07
EA200602257A1 (ru) 2007-04-27
IL179620A (en) 2013-04-30
BRPI0510526A (pt) 2007-10-30
ES2418833T3 (es) 2013-08-16
CN1993139B (zh) 2011-02-16

Similar Documents

Publication Publication Date Title
NO20065860L (no) Stabiliserte flytende interferonformuleringer
MY151121A (en) Hsa-free stabilized interferon liquid formulations
DE602006014990D1 (de) Intranasale verabreichung von schnell wirkendem insulin
WO2006051103A3 (en) Stable formulations of peptides
BRPI0510654A (pt) formulações de interferon em hidrogel
UA93349C2 (ru) Способ стабилизации мономерного белка интерферона
NO20080220L (no) Formuleringer med hoy medikament belastning og doseringsformer
MY142354A (en) Acidic insulin preparations having improved stability
DK1389137T3 (da) Sammensætninger til lungelægemiddellevering af protein
ATE382057T1 (de) Stabile formulierung von modifiziertem glp-1
BRPI0417684A (pt) composto, composição farmacêutica, e, uso de um composto
NO20054555D0 (no) Farmasoytiske preparater som omfatter syrestabilisert insulin
CY1107819T1 (el) Φαρμακευτικη διαμορφωση της ολανζαπινης
ES2422081T3 (es) Péptido Ser-Ser-Ser-Arg y sus utilizaciones medicinales
NO20054440L (no) Flytende formuleringer av tumornekrosefaktorbindende proteiner
HRP20050024A2 (en) Pegylated t20 polypeptide
DE60309480D1 (de) Vitamin d-analoge
AR034749A1 (es) Formulaciones de interferon beta humano
ATE455471T1 (de) Pulverförmige zusammensetzungen von fettlöslichen substanzen
DK1363676T3 (da) Fremgangsmåde til forögelse af administration af en terapeutisk nukleinsyre
NO20065853L (no) Hydrogelinterferonformuleringer
TH102367B (th) สูตรผสมอินเตอร์เฟียรอนที่เป็นของเหลวซึ่งถูกทำให้เสถียรโดยปลอด hsa
CY1114273T1 (el) Σταθεροποιημενα υγρα σκευασματα ιντερφερονης χωρις ανθρωπινη οροαλβουμινη
ATE424399T1 (de) Pharmazeutische zusammensetzungen von risperidon in wässriger lösung

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application